Published by Benjamin Chiou on 25th October 2023
(Sharecast News) - Pharma giant GSK has announced positive preliminary results from a trial of its Arexvy vaccine to treatment respiratory syncytial virus (RSV) disease for a younger patient population in the US.
URL: http://www.digitallook.com/dl/news/story/33860100/...